Like this quote in CEO report, seems to be confirming sales estimates:
"Sales of VitroGro® ECM in the UK and Europe can start quickly
once CE Mark is granted. Initially sales will be handled by
Company staff and some consultants who are already
working for Tissue Therapies. Hiring of new permanent sales
staff will proceed once CE Mark is granted.
CE Mark is also accepted by many countries (excluding the
USA) as sufficient regulatory approval for the submission of
applications for sale and this forms part of the global rollout
plan for VitroGro® ECM during 2015.
Efficient, scalable, commercial production of VitroGro® ECM
has been achieved and is ready for global supply.
Chronic skin wounds, particularly diabetic and venous ulcers
represent a large and rapidly growing global market for
which there are currently no definitive treatments.
The Company has had the benefit of the advice of a number
of expert and influential wound care clinicians in the UK,
Europe and elsewhere who are keen to use VitroGro® ECM as
soon as it is approved for sale.
Expert health economic analyses continue to produce strong
data to support the use and reimbursement of VitroGro® ECM
in the UK and Europe. This data is planned to be published
closer to sales launch.
All new data that has been developed reinforces the view that
VitroGro® ECM has the potential to transform the treatment
of chronic wounds. We look forward to the start of sales."
TIS Price at posting:
41.0¢ Sentiment: Buy Disclosure: Held